Equillium, Inc. Hits New 52-Week High of $2.70, Up 228% Yearly

Equillium, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 2.70 on March 16, 2026. This achievement marks a remarkable increase from its 52-week low of USD 0.27, showcasing a substantial year-over-year performance of 228.01%. In comparison, the S&P 500 has seen a more modest gain of 18.81% during the same period. Equillium's market capitalization stands at USD 106 million, reflecting its position within the microcap category. The company currently does not offer a dividend, and its financial metrics indicate a challenging landscape, with a negative return on equity of -78.92% and a debt-to-equity ratio of -1.06. The price-to-book ratio is reported at 3.42, further illustrating the company's valuation in the market. This notable price movement highlights Equillium's recent performance trends, positioning it as a noteworthy player in the biotechnology space.